do Indians complaining about it???I'm buying these drugs for My father,cause we know its not "Substandard"..even Doctors are prescribing these drugs.and if Cheap means "Poor Quality",then God save China.
and did we ask west to buy our drugs??they can have their own..like we're giving a "fkuc"..
by the way,same USA gave these Generic Drugs approval..
read this.............................................
Drugmakers from India, the biggest overseas source of medicines sold in the US, have got more than 100 generic drug approvals from the American health regulator FDA this year so far.
This has taken India’s share in the Original Abbreviated New Drug Application (ANDA) approvals to nearly 40 per cent in the US market so far in 2013, even as Indian companies are increasingly coming under the regulatory scanner here.
Since the beginning of 2013, the US Food and Drug Administration (FDA) has approved nearly 290 ANDAs allowing pharmaceutical firms to manufacture and sell generic drugs as a safe, effective and low-cost alternative to the Americans.
At least 110 of these approved applications are from the Indian companies, or entities owned or controlled by an Indian firm, the FDA data showed.
These companies include entities belonging to Sun Pharma group, Lupin, Aurobindo Pharma, Zydus, Glenmark, Dr Reddy’s, Emcure, Wockhardt, Torrent, Claris, Alkem, Ipca, Cipla, Famy Care, Natco, Hetero and Alembic.
The US market is home to generic drug spending of about USD 300 billion every year and India produces nearly 40 per cent of generic and over-the-counter products, while its share in the finished dosage medicine segment is about 10 per cent.
While the FDA has stepped up its efforts to ensure that only good quality medicines reach the American shores, the demand for generic drugs is surging under President Barack Obama’s healthcare programme.
With over 150 FDA-approved plants, including facilities run by MNCs, India shipped pharmaceutical products worth over USD 4 billion to the United States in 2012, year clocking a growth of around 30 per cent from the previous year.
Indian companies have tapped the US market by focusing on opportunities in plain-vanilla generics segment. However, many continue to improve their product offerings and look at alternative avenues to generate higher margins.
These include difficult-to-make products having technological entry barriers, as also niche products that require dedicated facilities and clinical trials and are not economically viable for many generic players.
Lupin was the top Indian drug seller in the American market last year by prescriptions, followed by Dr Reddy’s, Cadila Healthcare and Aurobindo Pharma, according to data compiled by IMS Health.
As the market for generic drugs, which usually sell at a fraction of cost to the original drugs, grows bigger with an estimated USD 100 billion worth medicines going off-patent over next 5 years, FDA has stepped up its inspections as well.
The new US laws requires FDA to inspect overseas plants on the same schedule as domestic facilities, and to bring an end to its big backlog of drug applications within 5 years.
Indian firms get FDA approval for 110 generic drugs - The Hindu
they're loosing the race.. and some member with delusion accusing its "Poor Quality"..
and then...it came......
Obama To India: Block Production Of Low-Cost Generic Drugs . . . Or Else
Millions of Americans struggle on a daily basis to afford medicine in the United States which is the highest in the world. Many seek affordable drugs by driving to Canada or seeking medicine (as well as medical care) in India. Yet, one of the first things that President Obama did in the new health care law was to
cave to a demand by the powerful pharmaceutical lobby to drop provisions guaranteeing cheaper medicine. The lobby then got
Congress to block two measures to guarantee affordable medicine. With billions at stake, Congress and the White House again yielded to the demands of this industry, which is sapping the life savings away of millions of families. Given this history, many are concerned about a meeting planned between Obama and the Prime Minister of India. Public interest groups object that Obama is threatening retaliation against India in the hopes of blocking one of the major alternatives for families in acquiring affordable medicine.
Congress has also again responded to industry demands for pressure in India to change its laws and, as a result, raise the cost of medicine.
Doctors Without Borders, a highly respected medical group, has denounced the effort of the Obama Administration as threatening basic health care for its own citizens and those around the world.
Obama will meet with Indian prime minister Manmohan Singh this week at the White House to demand a change to its intellectual property laws. In addition to a long record of yielding to the demands of the pharmaceutical industry, Obama
has also yielded to copyright and trademark hawks who has secured ever increasing criminal and civil penalties in the field. Here, the industry wants to cut off the supply of affordable medicine coming out of India due to its large generic drug industry. The industry is alarmed by the fact that India’s market is forcing the cost of drugs down for HIV, TB, and cancer by more than 90 percent.
Critics charge that Obama is basically reading from a script written by Pfizer and the industry in threatening retaliation if India does not change its intellectual property laws to limit the availability of generic drugs. There is no question that India’s legal system needs reform and intellectual property rules could be tightened. However, Doctors Without Borders insists that this is a raw effort to shutdown a country offering millions of people affordable medicine. If successful, the impact on the sick could be breathtaking if not life taking. Most AIDS drugs are generic and India supplies a huge amount of the HIV medicines.
The problem is that Indian courts have already supported the claims of Indian companies to produce such generics. For example, Novartis tried for seven years to block a low-cost generic salt form of the cancer drug imatinib, marketed as Gleevec. The Indian Supreme Court ruled that the company had every right to produce the drug and that the company, and by extension the U.S., was trying to impose effective monopoly pricing on consumers.
Likewise, a case involving Bayer shows how such inflated pricing works. Bayer lost an effort to block an Indian drug that slashed the cost of a kidney cancer drug by 97 percent. That’s right, 97 percent. Bayer wants to sell it as a cost of $4,500 per month.
Obama has increased the government paying for such drugs for the poorest Americans, but that healthcare deal still allowed drug companies to pull in windfall profits at public expense. Moreover, for middle income families, such costs (or the resulting higher insurance costs) have sapped away income at a time of diminishing wealth. The companies have a valid argument that some protection is needed to allow them to recoup billions in research to develop such amazing drugs. Intellectual property law encourage innovation by guaranteeing such profits that in turn encourage the investment in new research. However, with one of the most powerful lobbies in Washington (populated by former members and staff members who helped draft earlier laws), the drug industry has imposed obscene (and at times ruinous) costs on families who struggle to pay for life-sustaining medicine.
Doctors Without Borders is leading a campaign opposing Obama’s efforts to cut off the largest market for affordable drugs — a move that would leave families captive to the pricing set by these companies.
Obama To India: Block Production Of Low-Cost Generic Drugs . . . Or Else | JONATHAN TURLEY
but if you really wants to know China's contribution..here it is......
The stakes in drug regulation are high. In 2008, adulterated supplies of Heparin, an important blood thinner, led to the deaths of 80 people in the U.S. The problem was eventually traced to contaminated supplies from China.
U.S., India Clash Over Generic Drugs - WSJ.com
